New Delhi: NexCAR19, the world’s first humanised CAR-T therapy developed in India, has made gene therapies affordable and accessible while also maintaining scientific quality and patient safety, said the Ministry of Science and Technology on Wednesday.

NexCAR19 is a prescription drug for treating specific relapsed or refractory B-cell Non-Hodgkin’s Lymphomas and B-cell Acute Lymphoblastic Leukaemia when frontline therapy or other standard treatments have been unsuccessful. It was developed using a lentiviral vector.

“NexCAR19, India’s first living drug, has made gene therapies both affordable and accessible without compromising scientific rigour or patient safety,” the Ministry said.

NexCAR19, developed by ImmunoACT — a gene therapy company incubated at IIT Bombay — and supported by the

See Full Page